(Q36648048)

15 August 2017

1 reference

title

The detection and significance of minimal residual disease in acute and chronic leukemia (English)

1 reference

15 August 2017

Chung NG

1

1 reference

15 August 2017

Buxhofer-Ausch V

series ordinal

2

1 reference

15 August 2017

Radich JP

series ordinal

3

1 reference

15 August 2017

language of work or name

1 reference

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

68

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

371-385

1 reference

Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0039.2006.00714.X

10.1111/J.1399-0039.2006.00714.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference